Navigation Links
New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
Date:9/21/2011

uent in patients receiving 150 mg of BIBF 1120 twice daily than placebo and adverse events leading to discontinuation were mostly diarrhea, nausea and vomiting.

"People who suffer from IPF are in great need of a safe and effective treatment to preserve lung function so they can maintain physical activity and reduce the impact on their independence for as long as possible," said Luca Richeldi, MD, PhD, lead study author and director of the Research Centre for Rare Lung Diseases, University of Modena and Reggio Emilia, Modena, Italy. "The positive trends in slowing the decline in lung function over time, reducing the incidence of acute exacerbations and improving the quality of life with BIBF 1120 are a promising proof of concept."

BIBF 1120 received orphan-drug designation from the U.S. Food and Drug Administration in June 2011. Two pivotal phase III clinical trials are currently underway enrolling a total of 970 patients in 20 countries. The first patients entered the trials in April and May 2011, respectively. For more information about the phase III trials or to learn how to enroll, please visit clinicaltrials.gov (identifiers NCT01335464 and NCT01335477).

"The results of the phase II clinical trial for BIBF 1120 in IPF give us the confidence to continue assessing the compound's potential in phase III clinical trials," said Christopher Corsico, MD, MPH, senior vice president, Medicine and Regulatory, North America, Boehringer Ingelheim Pharmaceuticals, Inc. "Boehringer Ingelheim remains committed to identifying an effective treatment for IPF to help bridge the unmet therapeutic need for the thousands of people suffering from this fatal disease."

TOMORROW Data at ERS 2011 Annual Congress

The NEJM paper will be presented at the European Respiratory Society (ERS) 2011 Annual Congress on Monday, Sept. 26, 2011. Additional results of the TOMORROW trial will be presented during oral sessions at ERS on Sunday, Sept. 25, 2
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lung Cancer Study Reveals Similar Outcomes for African-American and Caucasian Patients Treated With Alimta®
2. Studying Fluid Overflow in Patients With Devices
3. Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
4. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
5. Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
6. The 62nd Annual Meeting of the American Association for the Study of Liver Diseases
7. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
8. First Patient Enrolled in SARcode Biosciences Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution
9. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
10. Breast Health Study Advances Safety Profile for Soy-Based Natural S-equol Supplement Designed to Manage Menopause Symptoms
11. Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014  Catalist-listed QT Vascular ... Group"), a developer and manufacturer of minimally invasive medical ... to announce that the Group has enrolled the first ... Germany . Multiple patients have already been enrolled ... at Auckland City Hospital, in Auckland, New ...
(Date:9/15/2014)... PDL BioPharma, Inc. (PDL) (NASDAQ: ... September 12, 2014, regular quarterly dividend payment of $0.15 per ... of September 5, 2014, the record date. ... portfolio of patents and royalty assets, consisting primarily of ... agreements with various biotechnology and pharmaceutical companies. PDL pioneered ...
(Date:9/15/2014)... Sept. 15, 2014 Research and Markets ... Drug Transfer Systems to 2020" report to their ... hazardous to humans has been receiving increasing amounts of ... substances become more clearly understood. For caregivers and their ... of attempts to mitigate exposure to cytotoxic drugs is ...
Breaking Medicine Technology:First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5PDL BioPharma Completes Regular Quarterly Dividend Payment 2Closed Drug Transfer Systems to 2020 2Closed Drug Transfer Systems to 2020 3
... Germany, Sept. 20, 2011 Weight and height, their ... for medical measuring and weighing. Now the company is ... integrating modern medical practices and hospital equipment. The new ... of precise data capture, transmission and interpretation of weight, ...
... – Ingenuity® Systems, a leading provider of ... researchers, today announced the addition of new ... miRecords , plus thousands of additional miRNA-mRNA ... The newly added content supplements existing experimentally ...
Cached Medicine Technology:seca 360 wireless - The New Era of Measuring and Weighing 2Ingenuity Announces New Additional MicroRNA Content to Complement First-of-its-Kind MicroRNA Filtering Capability in IPA 2
(Date:9/15/2014)... DALLAS, TX September 12, 2014 - An estimated ... disorder (PTSD) at some point during their lifetime. Brought ... PTSD is the result of altered chemistry and physiology ... a normal brain versus one altered by PTSD is ... from the Center for BrainHealth at The University of ...
(Date:9/15/2014)... 2014 The White House has recently ... offenders in jail and prison and toward helping them ... as a positive change. , The nation is currently ... abuse. According to an article from The Washington ... a shift away from using the criminal justice system ...
(Date:9/15/2014)... 2014 This year, Avenidas Village ... 2007. To mark the special occasion, Avenidas Village would ... village and helping it to get started seven years ... fun community for seniors. Members of Avenidas Village maintain ... in their own homes. They are able to have ...
(Date:9/15/2014)... Maureen Salamon HealthDay ... -- Pediatricians prescribe antibiotics about twice as often as ... infections, a new study indicates. More than 11 ... teens may be unnecessary, according to researchers from University ... use not only fails to eradicate children,s viral illnesses, ...
(Date:9/15/2014)... By Amy Norton ... -- A relatively small number of medications are responsible for ... ingestion, a U.S. government study finds. Each year between ... years were hospitalized after getting a hold of family members, ... Prevention. "Three-quarters of those children were just 1 ...
Breaking Medicine News(10 mins):Health News:EEG study findings reveal how fear is processed in the brain 2Health News:White House Shifts Policy on Drugs 2Health News:Avenidas Village Celebrates Anniversary 2Health News:Kids Prescribed Antibiotics Twice as Often as Needed, Study Finds 2Health News:Kids Prescribed Antibiotics Twice as Often as Needed, Study Finds 3Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 2Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 3
... and Highlights Potential Factors that Affect Health Outcomes, in ... N.J., Jan. 14 Results from the LATINO study, ... the hepatitis C virus (HCV), were published today in ... This Roche study demonstrated that HCV can be successfully ...
... considerable reduction in infection rates, , , WEDNESDAY, Jan. 14 ... life-threatening infection, have declined substantially since a new vaccine ... The declines have been seen not only in children ... herd immunity effect, the researchers noted. To assess the ...
... 14 Home Care Assistance has,partnered with a ... consistently high rankings in sponsored and organic searches ... that delivers thousands of,leads critical to franchisee business ... commitment to provide solutions that offer immediate,business results ...
... of Inauguration Day, Berry,Chill is offering free Berry Obama ... , The Berry Obama is ... with blueberries, blue candy-covered almonds, and blue,sprinkles to reflect ... the special combination will be topped with fresh pomegranate,coconut ...
... 14 A surge of arctic air forecast to ... chills that could lead to serious health problems, the ... to range from the single digits to minus 10 ... to 30 below zero. "Taking preventive action can help ...
... Benzoyl Peroxide Wash to Utilize MICROSPONGE(R) Delivery SystemCARLSBAD, ... the launch of NeoBenz Micro Wash, ... with the MICROSPONGE (R) delivery system, for ... NeoBenz Micro Wash contains 7% benzoyl ...
Cached Medicine News:Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 2Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 3Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 4Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 5Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 6Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 7Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 8Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 9Health News:Meningitis Vaccine Seems to Work Like a Charm 2Health News:Meningitis Vaccine Seems to Work Like a Charm 3Health News:Home Care Franchise Forms Strategic Partnership with Google(TM) 2Health News:Inauguration Day Deal: Get a Free Berry Obama Chilled Yogurt at Berry Chill 2Health News:Department of Health Urges Pennsylvanians to Prepare For Dangerously Cold Weather 2Health News:SkinMedica(R) Launches NeoBenz(R) Micro Wash for Acne 2Health News:SkinMedica(R) Launches NeoBenz(R) Micro Wash for Acne 3
... unique system uses prolene as thread-guide reducing ... The hollow Ritleng Probe is inserted into ... thread-guide is fed through it. The probe ... to pull the silicone tubing in place. ...
... For canalicular laceration or imperforate ... and Stainless Steel Probe. Box ... securely swaged into malleable stainless ... by punctum plug: no knots, ...
For Canalicular Stenosis. Non-traumatic tip. Silicone tubing swaged into probe. Note: Tubing securely swaged into malleable stainless steel probes. Medical grade silicone. Box of 3, sterile....
Recommended to insert plug portion of all monocanalicular intubation systems into punctum....
Medicine Products: